Correction: Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma - Top-Institutions - MDSpire

Correction: Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma

  • By

  • Ping Huang

  • Fenping Zhang

  • Yuchun Lin

  • Jie Peng

  • Zesong Yang

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology

  • #2

    First Affiliated Hospital of Chongqing Medical University
    First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

    Key Differentiators

    • Hematology

  • #3

    Fengdu County Traditional Chinese Medicine Hospital
    Fengdu County Traditional Chinese Medicine Hospital

    Fengdu, China

    Key Differentiators

    • Hematology

Original Source(s)

Correction: Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma

  • by Ping Huang, Fenping Zhang, Yuchun Lin, Jie Peng, Zesong Yang

  • June 10, 2026

Related Content

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min